Chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable potential in treating high-risk smoldering multiple myeloma (SMM), according to recent findings from a phase 2 trial. This innovative approach has conferred sustained benefits to patients, leading to unprecedented outcomes that surpass prior treatment expectations.
Breakthrough Results
In this trial, participants received a single infusion of ciltacabtagene autoleucel (Carvykti; Johnson & Johnson, Legend Biotech) without any prior induction or bridging therapy. Remarkably, every patient achieved minimal residual disease (MRD) negativity within two months of treatment. Notably, by the data cutoff date, all individuals remained MRD negative, with none progressing to active multiple myeloma. These results were presented at the American Association for Cancer Research Annual Meeting, illustrating the potential of CAR-T therapy in this challenging patient population.
Dr. Omar Nadeem, a medical oncologist at Dana-Farber Cancer Institute and the study’s first author, expressed astonishment at the findings. “We anticipated better results than previous therapies, but these outcomes far exceed our expectations,” he stated. The rapid and profound responses observed in all patients highlight the therapy’s transformative potential.
Understanding Smoldering Multiple Myeloma
Smoldering multiple myeloma is an asymptomatic condition characterized by abnormal plasma cells in the bone marrow. Approximately 0.5% of adults over 40 years old are affected, with higher incidence rates in men and non-Hispanic Black individuals. Patients classified as high-risk SMM have a significant chance—about 50%—of progressing to active multiple myeloma within two years. Traditionally, these patients were monitored through active surveillance, receiving treatment only after the onset of debilitating symptoms.
Dr. Irene Ghobrial, a senior author of the study and professor of medicine at Dana-Farber, emphasized the urgency of addressing this issue. “Patients often ask, ‘What are you waiting for?’ It’s time to reconsider the approach of waiting for symptoms before initiating treatment,” she noted. The approval of new therapies over the past decade has sparked a shift in mindset, aligning treatment strategies with patient needs.
A Shift in Treatment Paradigms
The recent approval of daratumumab for high-risk SMM marked a significant milestone in treatment options. This subcutaneous therapy was demonstrated to delay progression to active myeloma by 51% over five years compared to active monitoring. However, the therapy requires regular administration for three years, with less than 10% of patients achieving a complete response, raising questions about its long-term effectiveness.
With this context, the CAR-PRISM trial was initiated to explore the efficacy and safety of cilta-cel in high-risk SMM patients. The therapy targets the B-cell maturation antigen (BCMA) present on dysfunctional plasma cells, with the hypothesis that administering CAR-T therapy before symptom development might yield enhanced efficacy and safety.
Trial Design and Patient Outcomes
The CAR-PRISM trial enrolled 20 participants with a median age of 58. They received standard lymphodepletion chemotherapy followed by a single infusion of cilta-cel at varying doses. The primary endpoint was safety, while secondary endpoints included the objective response rate, complete response rate, MRD negativity, progression-free survival (PFS), and adverse events.
All patients experienced mild cytokine release syndrome, with no severe complications. The most significant hematologic adverse events included neutropenia and leukopenia, but no patients experienced delayed hematologic toxicity or immune-effector cell-associated neurotoxicity syndrome (ICANS).
Encouragingly, all participants achieved MRD negativity within two months, a hallmark of long-term treatment success. A median follow-up of 15.3 months revealed that twelve patients maintained MRD negativity after one year, with six remaining MRD negative after 18 months. Additionally, all patients met the objective response criteria, with 90% achieving a complete or stringent complete response.
Addressing Limitations and Future Directions
While the trial’s outcomes are promising, researchers acknowledged certain limitations, including the small patient cohort and the short follow-up duration. The single-arm design and exclusion of patients with higher plasma cell infiltration also warrant consideration when interpreting the results. However, the findings support the premise that early administration of CAR-T therapy can lead to profound responses.
Moving forward, the CAR-PRISM trial serves as a proof of concept, paving the way for further studies to assess the long-term durability of responses and the overall risk-benefit ratio of cilta-cel in this context. Dr. Nadeem highlighted the importance of shifting the treatment paradigm towards earlier intervention, stating, “Dr. Ghobrial has worked tirelessly for over a decade to promote early therapy.”
Looking Ahead
Research efforts are expanding, with ongoing studies in Spain investigating cilta-cel in patients with high-risk SMM who previously received induction therapy. The combination of these results with the CAR-PRISM data could further enhance the enthusiasm surrounding CAR-T and immunotherapy options for high-risk smoldering myeloma.
In conclusion, the CAR-PRISM trial underscores the potential of CAR-T therapy in addressing smoldering multiple myeloma. As researchers continue to explore this avenue, there is hope for transitioning multiple myeloma into a preventable condition through early detection and intervention.
- Key Takeaways:
- CAR-T therapy demonstrates high efficacy in achieving MRD negativity for high-risk SMM.
- A shift towards early treatment for smoldering multiple myeloma is gaining traction.
- Ongoing research will clarify the long-term benefits and risks associated with CAR-T therapy.
The journey toward transforming multiple myeloma treatment is just beginning, and the ongoing commitment to innovation and patient-centered care holds promise for a better future.
Read more → www.healio.com